Azacitidine clinical trials
Also written Vidaza, NSC-102816, Onureg and U-18496.
Includes 44 studies of Cc-486.
How each study uses Azacitidine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Azacitidine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 19 May 2004 · VIDAZA · NDA 050794 (FDA, Drugs@FDA)
- European Union
- 17 Dec 2008 · Vidaza · EMEA/H/C/000978 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
437 studies that test it; most in 2026 (43); 4 more planned to start later
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2000 | 5 |
| 2003 | 1 |
| 2005 | 11 |
| 2006 | 13 |
| 2007 | 8 |
| 2008 | 15 |
| 2009 | 16 |
| 2010 | 24 |
| 2011 | 18 |
| 2012 | 15 |
| 2013 | 18 |
| 2014 | 8 |
| 2015 | 21 |
| 2016 | 12 |
| 2017 | 16 |
| 2018 | 19 |
| 2019 | 17 |
| 2020 | 20 |
| 2021 | 23 |
| 2022 | 29 |
| 2023 | 23 |
| 2024 | 32 |
| 2025 | 29 |
| 2026 | 43 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 74 · Other 367
M.D. Anderson Cancer Center (42) · National Cancer Institute (NCI) (29) · Celgene (28) · The First Affiliated Hospital of Soochow University (19) · Groupe Francophone des Myelodysplasies (10) · Institute of Hematology & Blood Diseases Hospital, China (10) · AbbVie (7) · Memorial Sloan Kettering Cancer Center (6)
Often tested with
Tested in the same studies.
Venetoclax (111) · Cytarabine (35) · Lenalidomide (21) · Decitabine (17) · Tucidinostat (14) · Gilteritinib (11) · Daunorubicin (10) · Ivosidenib (10)
Related medicines
As reviewed, each with the page that says it.
- One of Antimetabolites source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 3 phase 3 studies under way
Azacitidine is the comparator. A study of two new drugs counts under both.
- 1Galinpepimut-s · Sellas Life Sciences Group
- 1Cytarabine · Ruijin Hospital · next primary completion Jul 2028
- 1Granulocyte Colony-Stimulating Factor · Ruijin Hospital · next primary completion Jul 2028
- 1Clifutinib · Sunshine Lake Pharma Co., Ltd. · next primary completion Nov 2027
Reaching primary completion within a year · 46, 5 in phase 3
Studies that test Azacitidine, phase 3 first.
- Dec 2026Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AMLPhase 3 · The First Affiliated Hospital of Soochow University
- Mar 2027Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell LymphomaPhase 2/3 · National Cancer Institute (NCI)
- Sep 2027Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid LeukaemiaPhase 3 · Chinese PLA General Hospital
- Oct 2027An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.Phase 3 · Servier Affaires Médicales
- Nov 2027Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 MutationPhase 3 · Institut de Recherches Internationales Servier
- Nov 2026Venetoclax in Patients With MDS or AML in Relapse After AHSCTPhase 1/2 · Groupe Francophone des Myelodysplasies
- Nov 2026A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With PlasmacytomaPhase 2 · Memorial Sloan Kettering Cancer Center
- Dec 2026Repurposing 5-Azacytidine for the Treatment of Muscle Contractures in Children With Cerebral PalsyPhase 1 · Shirley Ryan AbilityLab
- Dec 2026Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCTPhase 2 · Institute of Hematology & Blood Diseases Hospital, China
- Dec 2026A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDSPhase 2 · Karolinska University Hospital
Studies
Open first, then newest update. How each study uses Azacitidine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 441
- Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating AgentRecruitingPhase 2University of California, DavisNCT07304011Written as Azacitidine
- Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLRecruitingPhase 3Kura Oncology, Inc.NCT07007312Written as Azacitidine (AZA)
- A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell LymphomasRecruitingPhase 1/2The Lymphoma Academic Research OrganisationNCT07018752Written as azacitidine
- Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05554406Written as Azacitidine
- Azacitidine and Abatacept in Relapsed or Refractory T-Cell LymphomaRecruitingPhase 1National Cancer Institute (NCI)NCT07388563Written as azacitidine
- BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast CancerRecruitingPhase 2University of Illinois ChicagoNCT04891068Written as Azacitidine
- Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AMLNot yet recruitingPhase 2UNC Lineberger Comprehensive Cancer CenterNCT07605949Written as Azacitidine
- Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-InequalityRecruitingPhase 4Virginia Commonwealth UniversityNCT06370000Written as Oral Azacitidine
- tSCS and 5-Azacitidine for Enhanced Motor Outcomes in Cerebral PalsyRecruitingPhase 2Shirley Ryan AbilityLabNCT07433023Written as 5-Azacitidine
- Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell LymphomaRecruitingPhase 2Alliance for Clinical Trials in OncologyNCT04803201Written as Oral azacitidine
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05564390Written as Azacitidine
- Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell LymphomaRecruitingPhase 1City of Hope Medical CenterNCT07691450Written as Azacitidine
- FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid LeukemiaRecruitingPhase 1Fred Hutchinson Cancer CenterNCT07645469Written as Azacitidine
- Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05554393Written as Azacitidine
- Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade GliomaEnrolling by invitationPhase 1Andrew P. GrovesNCT06896110Written as Azacitidine (AZA)
- Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative NeoplasmsNot yet recruitingPhase 1Roswell Park Cancer InstituteNCT07679334Written as Azacitidine
- Sonrotoclax Plus Azacitidine in Patients With MDS-IB2RecruitingPhase 1/2Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineNCT07885397Written as Azacitidine (AZA)
- Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDSRecruitingPhase 1Stelexis BioSciencesNCT06533761Written as Eganelisib in combination with azacitidine
- Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like PatientsRecruitingPhase 2The First Affiliated Hospital of Soochow UniversityNCT07159620Written as Azacitidine (AZA)
- A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in MDS/AML With TP53 MutationsRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT07646821Written as Azacitidine (AZA)
See all 441 studies that test Azacitidine →
Given beside what is tested · 261 — Azacitidine is usual care or a partner of the new treatment
- Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic SyndromesRecruitingPhase 2Faron Pharmaceuticals LtdNCT07672769Written as azacitidine
- Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)RecruitingPhase 3PETHEMA FoundationNCT07478991Written as Azacitidine
- A Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) PatientsRecruitingPhase 3Beijing InnoCare Pharma Tech Co., Ltd.NCT07925190Written as Azacitidine (AZA)
- Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT06317649Written as Azacitidine
- Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic LeukemiaRecruitingPhase 1/2Uma BorateNCT06523556Written as Azacitidine
- Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received VenetoclaxRecruitingPhase 2Timothy PardeeNCT07471841Written as Azacitidine (AZA)
- A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)RecruitingPhase 3Janssen Research & Development, LLCNCT06852222Written as Azacitidine (AZA)
- A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML PatientsNot yet recruitingPhase 1Cullinan Therapeutics Inc.NCT07722767Written as Azacitidine
- A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDSRecruitingPhase 1Apollo Therapeutics LtdNCT06372717Written as Azacitidine and APL-4098
- A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic LeukemiaNot yet recruitingPhase 1/2BeOne MedicinesNCT07770698Written as Azacitidine
- Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia PatientsRecruitingPhase 3Institute of Hematology & Blood Diseases Hospital, ChinaNCT07132684Written as Azacitidine
- Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AMLRecruitingPhase 3Institute of Hematology & Blood Diseases Hospital, ChinaNCT07539818Written as Azacitidine
- Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid LeukemiaRecruitingPhase 1St. Jude Children's Research HospitalNCT06177067Written as Azacitidine
- A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)RecruitingPhase 2/3AbbVieNCT07581002Written as Azacitidine
- Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).RecruitingPhase 3Ascentage Pharma Group Inc.NCT06641414Written as Azacitidine Injection
- Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AMLRecruitingPhase 2Beijing 302 HospitalNCT07078591Written as Azacitidine (AZA)
- A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)RecruitingPhase 1M.D. Anderson Cancer CenterNCT06616636Written as Azacitidine
- A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)RecruitingPhase 2/3Taiho Oncology, Inc.NCT04256317Written as Azacitidine
- Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AMLRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT07508982Written as Azacitidine
- A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid LeukemiaRecruitingPhase 1City of Hope Medical CenterNCT06763341Written as Azacitidine
Showing 20 of 261.
As the comparator · 13 — what is tested is compared with Azacitidine
- Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPNRecruitingPhase 2Virginia Commonwealth UniversityNCT07710534Written as Azacitidine plus venetoclax (AZA+VEN)
- Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AMLNot yet recruitingPhase 3Ruijin HospitalNCT07735117Written as azacitidine
- HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AMLRecruitingPhase 3Sunshine Lake Pharma Co., Ltd.NCT05586074Written as Azacitidine
- Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid LeukemiaRecruitingPhase 2The First Affiliated Hospital of Soochow UniversityNCT06532552Written as VA
- Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AMLCompletedPhase 2GWT-TUD GmbHNCT04061239Written as Azacitidine
- Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th SalvageTerminatedPhase 3Delta-Fly Pharma, Inc.NCT03926624Written as Azacitidine
- A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) MutationCompletedPhase 3Astellas Pharma Global Development, Inc.NCT02421939Written as Azacitidine
- Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2Active, not recruitingPhase 3Sellas Life Sciences GroupNCT04229979Written as Azacitidine
- Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs VidazaCompletedPhase 1American Regent, Inc.NCT01290302Written as Vidaza®
- Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive ChemotherapyWithdrawnPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT06770257Written as Azacitidine
- An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 MutationCompletedPhase 3CelgeneNCT02577406Written as Azacitidine
- Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid MalignancyStatus unknownPhase 4Shenzhen Second People's HospitalNCT03873311Written as Azacytidine
- Best Promising Drug Association With Azacitidine in Higher Risk Myelodysplastic SyndromesStatus unknownPhase 2Assistance Publique - Hôpitaux de ParisNCT01342692Written as Azacitidine
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
Newly registered1
- Sonrotoclax Plus Azacitidine in Patients With MDS-IB2Oct 21, 2026NCT07885397
Codes
What other systems call Azacitidine · ClinicalTrials.gg INT007036
- MeSH (NLM) D001374AzacitidineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) M801H13NRUAZACITIDINEConfirmed FDA, NLM, Wikidata
- RxNorm 1251Confirmed FDA, Wikidata
- Wikidata Q416451azacitidineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C288AzacitidineOne source FDA
- DrugBank DB00928One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D001374 | Azacitidine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | M801H13NRU | AZACITIDINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1251 | — | Confirmed FDA, Wikidata |
| Wikidata | Q416451 | azacitidine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C288 | Azacitidine | One source FDA |
| DrugBank | DB00928 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.